The effect of carbon dioxide (CO 2 ) on cerebral metabolism is of tremendous interest to functional imaging. In particular, mild-to-moderate hypercapnia is routinely used in calibrated blood oxygenlevel dependent (BOLD)-functional magnetic resonance imaging (fMRI)-based quantification of cerebral oxidative metabolism changes (DCMRO 2 ), and relies on the assumption of a stable CMRO 2 during CO 2 challenges. However, this assumption has been challenged by certain animal studies, necessitating its verification in humans and under conditions customary to fMRI. We report, for the first time, on global DCMRO 2 measurements made noninvasively in humans during graded hypercapnia and hypocapnia. We used computerized end-tidal CO 2 modulation to minimize undesired concurrent changes in oxygen pressure, and our findings suggest that no significant change in global CMRO 2 is expected at the levels of end-tidal CO 2 changes customary to calibrated BOLD.
Introduction
Carbon dioxide (CO 2 ) is a potent vasodilator, and its effect on cerebral metabolism is of great interest. Notably, hypercapnia is routinely used in calibrated blood oxygen-level dependent (BOLD) functional magnetic resonance imaging (fMRI) for estimating changes in cerebral oxygen metabolism (DCMRO 2 ), but this methodology is contingent upon the assumption of negligible DCMRO 2 during hypercapnia-induced cerebral blood flow (CBF) increases (Davis et al, 1998; Hoge et al, 1999) . Although CMRO 2 behavior under manipulations of end-tidal partial pressure of CO 2 (PETCO 2 ) has been investigated previously in animals (Hino et al, 2000; Horvath et al, 1994; Jones et al, 2005; Martin et al, 2006; McPherson et al, 1991; Yang and Krasney, 1995; Zappe et al, 2008) , the wide range of anesthetic agents used, compounded by the diverging levels of PETCO 2 perturbations involved, has made it difficult to draw definitive conclusions regarding the CMRO 2 response during hypercapnia and hypocapnia with regard to human fMRI. Furthermore, the sampling intervals in these experiments were largely inadequate to capture the dynamic CMRO 2 changes related to transient metabolic responses, and the PETCO 2 manipulations were too severe to be directly interpreted for human fMRI.
In spite of this need for verification, CMRO 2 invariability has yet to be established for the range of PETCO 2 values relevant for functional imaging, as the corresponding experiments are technically demanding. Conventionally, human cerebral oxidative metabolism has been assessed invasively through arteriovenous blood oxygenation differences, obtained through internal jugular catheterization. In this study, we build on this well-established concept, and estimate CMRO 2 changes from flow and oxygenation data using a magnetic resonance-equivalent of the Kety-Schmidt technique. In particular, we use pulsed arterial-spin labeling (PASL), phase-contrast (PC) flow imaging, as well as in vivo magnetic resonance oximetry to measure whole-brain CBF and CMRO 2 changes noninvasively in awake humans during graded hypercapnia and hypocapnia. We show that at the levels of PETCO 2 perturbations routinely used in calibrated BOLD, there is no significant global change in CMRO 2 .
Materials and methods
All acquisitions were performed using a Siemens Trio 3-T system (Siemens, Erlangen, Germany) on 10 healthy adult subjects (age = 25.3±3.6 years, 5 women) who gave informed consent according to the protocols specified by our Institutional Review Board. The body coil was used for radio frequency transmission and a phased-array neurovascular coil for reception. A three-dimensional 1-mm isotropic resolution T 1 -weighted (FLASH (fast low-angle shot)) scan served as the anatomic reference for each subject. Venous blood T 2 was obtained in vivo for each subject in both jugular veins (at the neck level, immediately above the facial vein drainage) using a magnetizationprepared segmented echo-planar imaging sequence (Chen and Pike, 2009; Stefanovic and Pike, 2004) . From these T 2 measurements, venous oxygenation (Y) was estimated using the calibration relationship (T 2 dependence on blood oxygenation and Carr-Purcell-Meiboom-Gill (CPMG) refocusing interval) obtained by Chen and Pike (2009) based on in vitro whole human blood relaxometry (Chen and Pike, 2009) and the weak field-inhomogeneity diffusion model (Jensen and Chandra, 2001) . Each oximetry measurement lasted 4.5 minutes. In addition, DCBF changes were measured using PICORE (proximal inversion with a control for off-resonance effects)-QUIPSS (quantitative imaging of perfusion using a single subtraction) II PASL with asymmetric BASSI (bandwidth-modulated adiabatic selective saturation and inversion) saturation/inversion (Warnking and Pike, 2006) and ASSIST (attenuating the static signal in arterial spin tagging) background suppression (Ye et al, 2000) . The imaged slab was positioned approximately parallel to the AC-PC (anterior commissure-posterior commissure) line. It covered 8 slices of 5 mm (separated by 1-mm gaps), with field of view = 256 mm, matrix size = 64 Â 64, repetition time = 5 seconds, TI 1 (inversion time) = 700 milliseconds, TI 2 = 1,300 milliseconds, echo time = 25 milliseconds, labeling thickness = 150 mm, and labeling gap = 5 mm. Using the 'Head' and 'Neck' modes of the neurovascular coil, we optimized the signal-to-noise characteristics for both whole-brain and neck-level acquisitions.
Mild and moderate levels of hypercapnia and hypocapnia were induced through the administration of mixtures of CO 2 and medical air using the RespirAct breathing circuit (Thornhill Research, Toronto, ON, Canada), which provided computerized and independent targeting of PETCO 2 and PETO 2 (partial pressure of end-tidal oxygen) based on sequential gas delivery (Slessarev et al, 2007) . This device provided high stability in PETCO 2 targeting, while maintaining significantly more constant PETO 2 levels than manual methods, both of which are crucial to the accurate quantification of CMRO 2 changes due solely to PETCO 2 changes. Each 12-minute PASL measurement consisted of three (60 seconds off:180 seconds on:120 seconds off) paradigms. In addition, two-dimensional cine PC flow data were obtained from five subjects in the internal carotid and vertebral arteries. These vessels account for the majority of cerebral inflow, and the corresponding PC acquisition (2.5 minutes) was used for cross-validation with the PASL data as a measure of global CBF. A finger pulse oximeter provided cardiac triggering and arterial oxygen data.
For each functional run of each subject, subject-specific brain masks were derived by applying an intensity threshold to the PASL control images. The resultant masks were manually verified to ensure exclusion of extracerebral structures, and applied to the PASL data to assess global flow changes. Using the venous Y measurements, DCMRO 2 and the neurovascular coupling ratio were estimated on the basis of equation (1), which was derived from the Fick principle (Kety and Schmidt, 1948) ,
where C = DCMRO 2 /DCBF, Y a and Y 0 are arterial and baseline venous oxygenation levels, respectively. Unconstrained weighted nonlinear least-square curve-fitting (trust-region method) was used to fit the data to the model, with weightings proportional to the inverse s.d. of the individual measurements. All statistical analyses were performed after outlier removal.
Results and Discussion
Typical PASL, internal jugular venous relaxometry, and internal-carotid PC flowmetry images are shown in Figure 1 . The average estimated baseline venous oxygenation (Y 0 ) was 58.2% ± 8.2% (mean ± s.d.), corresponding to an average normocapnic PETCO 2 of 39.9±1.4 mm Hg. The mean measured Y a as assessed using pulse oximetry was B98%, in line with literature values (Valdez-Lowe et al, 2009; Wagener and Hendricker, 1987) . The DPETCO 2 measurements associated with all four levels of challenge, namely mild and moderate hypercapnia and hypocapnia, as categorized by fuzzy-cluster classification of the measured DPETCO 2 values, are summarized in Table 1 . Stability in PETO 2 was maintained during PETCO 2 manipulations in all cases, as exemplified in Figure 2 . The corresponding DCBF and DY measurements are also listed in Table  1 . A significant difference in DPETCO 2 was found between mild and moderate hypercapnia (P = 3.42 Â 10 À10 ), as well as between mild and moderate hypocapnia (P = 9.74 Â 10 À8 ). The same was true for DCBF (P = 7.92 Â 10 À7 ) and DY (P = 5.01 Â 10 À4 ) for hypercapnia, but not for hypocapnia (mild versus moderate hypocapnia, P = 0.11 and P = 0.43 for DCBF and DY differences, respectively). In general, the vascular reactivity to hypercapnia was higher than to hypocapnia, reflected by the DCBF:DPETCO 2 ratios (P = 0.004). However, the DY:DCBF ratios were higher for hypocapnia than for hypercapnia (P = 0.01). These two ratios were not significantly modulated by the severity of the challenge. Whole-brain PASL DCBF in the whole-brain masks and PC flow measurements were found to be equivalent, as detailed in Table 2 . Using PASL-based global DCBF, global DCMRO 2 and C values were estimated for each challenge. The DCMRO 2 values computed on the basis of equation (1), did not differ significantly between mild and moderate levels of hypercapnia (P = 0.11) or hypocapnia (P = 0.40). Neither differences were observed when comparing between mild and moderate (hypercapnia + hypocapnia) challenges (P = 0.21), but DCMRO 2 during hypercapnic and hypocapnic (mild + moderate) challenges were found to differ (P = 0.04). This trend remained when comparing hypercapnic and hypocapnic conditions solely at the moderate level, but did not reach statistical significance (P = 0.06). With regard to the extent of CBF-CMRO 2 coupling, no significant difference in C was found between mild and moderate hypercapnia (P > 0.99); similar findings apply to mild and moderate hypocapnia Hypocapnia versus hypercapnia P = 0.004* P = 0.01* P > 0.99 P = 0.04* Mild versus moderate challenges P = 0.29 P = 0.18 P > 0.99 P = 0.21 CBF, cerebral blood flow; DCMRO 2 , cerebral oxidative metabolism change; PETCO 2 , end-tidal partial pressure of CO 2 . The means were weighted by the inverse of the measurement uncertainties. No significant difference in C was found between mild and moderate hypercapnia (P > 0.99), or between mild and moderate hypocapnia (P > 0.99). Moreover, the C estimates computed from all hypercapnic (C = À0.12±0.11, mean±s.d.) and from all hypocapnic (C = 0.06±0.30) cases did not differ significantly (P > 0.99). , wherein in vivo jugular oximetry was also performed. A typical CBF activation t-map obtained from PASL and a brain mask derived through intensity thresholding are shown in B and C, respectively. The PASL measurements were validated using phase-contrast magnetic resonance imaging (MRI) measurements in the internal carotid (ICAs) and vertebral arteries (VAs), labeled in D. Finally, venous blood oxygenation measurements were performed using internal jugular vein (IJV) MR oximetry (E).
(P > 0.99). Similarly, the values of C computed from all hypercapnic (C = À0.12±0.11) and from all hypocapnic (C = 0.06 ± 0.30, mean ± s.d.) cases did not differ significantly (P > 0.99). Thus, a single fit was performed on data across all subjects and challenges, yielding C = À0.12 ± 0.14, with a correlation of 0.78 and a root-mean-squared error of 1.37% (Figure 3) , which is indistinguishable from zero (P > 0.99). We did not observe a significant difference (P > 0.99) between C estimated using PASL and PC flowmetry (C = 0.02±0.17). Finally, assuming C = 0, and using the measured DCBF, the expected venous oxygenation was calculated on the basis of equation (1) for all conditions. The resulting Y values were not significantly different from the corresponding measured values (P = 0.48). We further noted that although we adopted the group mean arterial oxygenation of 98% for these calculations, coinciding with commonly assumed values (Hoogenraad et al, 1998) , our observations were robust against physiologically plausible variations in arterial oxygenation. For Y a varying between 96 and 100%, the resultant fractional uncertainties DCMRO 2 and C were both within B10%.
Our measurement of cerebral venous oxygenation (Y) by T 2 -based magnetic resonance oximetry was in good agreement with jugular bulb measurements (McCormick et al, 1991) , and covaried with CBF. Moreover, the comparability between PASL and PC measurements of the CBF response to graded hypercapnia and hypocapnia supports the use of PASL for measuring whole-brain CBF changes. In addition, our observations of cerebral vascular reactivity to hypercapnia are in line with previous reports (McPherson et al, 1991; Noth et al, 2006) . Our flow and oximetry methodology derives from principles similar to those shown recently by Xu et al (2009) , although venous flow was used in the latter case and is customarily more challenging to assess than arterial flow. Notwithstanding, a unique advantage of our methodology is our strict control of PETO 2 during CO 2 manipulations. It is well known that conventional approaches to PETCO 2 manipulation can introduce nonnegligible variations in PETO 2 ; increases in PETO 2 , consistently observed during hypercapnic challenges in the literature, can effectively undermine the effect of CO 2 (Losert et al, 2002) and hence can introduce biases in DCBF. In this study, we continuously monitored and minimized changes in PETO 2 through the use of computerized targeting facilitated by RespirAct, and were therefore able to achieve the isolation of CO 2 effects, which is a key requirement for the experiment at hand, and constitutes a basic assumption in numerous fMRI experiments using CO 2 challenges. Our results suggest that there are no significant alterations in global CMRO 2 due to these challenges, consistent with predictions obtained using the deoxyhemoglobin dilution model (Hoge et al, 1999) . Although the current measurements show an absence of substantial global CMRO 2 modulation by low levels of PETCO 2 modulation, they do not preclude the possibility of spatial heterogeneities in the CMRO 2 response to capnic challenges. For instance, a slight increase in neuronal activity modulations by fluctuating inhaled CO 2 in the pons and medulla may occur, while decreases in motor synaptic synchrony (Biswal et al, 1997) have also been observed, potentially linked to CO 2 -mediated suspension in oxidative metabolism fluctuations (Hudetz et al, 1998) and slight alterations in the intrathalamic network (Steriade et al, 1996) . On the basis of our experimental observations, we expect the spatial distribution and the magnitude of this response to also exhibit sizeable subject dependence. In view of the sources of variation, we sought to assess group trends, and to verify whether the assumption of negligibility of DCMRO 2 globally is reasonable for the purpose of calibrated BOLD.
Several animal studies, invaluable precursors to similar experiments in humans, document the CMRO 2 response during hypercapnic challenges, but thus far, the conclusions have been inconsistent. The CMRO 2 invariability was reported by Hino et al (2000) , McPherson et al (1991) , and Yang and Krasney (1995) , in anesthetized lambs and dogs, as well as in awake sheep, respectively, at DPETCO 2 values of up to 30 mm Hg. In contrast, Horvath et al (1994) showed a B30% decrease in CMRO 2 in anesthetized rats (DPETCO 2 E50 mm Hg), whereas Jones et al (2005) found a 30% CMRO 2 increase during 10% hypercapnia in anesthetized rats (8 minutes, DPETCO 2 E50 mm Hg), and negligible DCMRO 2 at 5% CO 2 (DPETCO 2 E25 mm Hg). The latter result was corroborated by findings in awake rats by Martin et al (2006) (5% CO 2 ), but questioned by data obtained from the study by Zappe et al (2008) , which showed a B15% CMRO 2 reduction during 6% CO 2 (DPET-CO 2 = 24 mm Hg) in anesthetized macaques. These variations in outcome can in part be attributed to the substantial methodological differences, because: (1) different types of anesthesia and states of alertness can alter the neuronal response significantly and (2) the levels and durations of PETCO 2 manipulations across these studies varied substantially (the duration varying from 60 seconds to 96 hour). More importantly, the comparatively high severity of the above PETCO 2 perturbations preclude comparability with commonly used human fMRI paradigms. Further complications stem from evidence in the literature that the general response to inhaled CO 2 may be highly species-and subject-dependent, as a 5% CO 2 challenge in awake humans rarely produces as much as a 25 mm Hg PETCO 2 increase. Given these considerations, we regard the widely varying experimental protocols to be a key potential contributor to the discrepancies among animal and human literature, which must be interpreted with care.
In summary, in this study, we sought to address accurate DCMRO 2 measurement during hypercapnia and hypocapnia in awake humans, which has traditionally been hindered by nontrivial methodological challenges, particularly, the reproducible targeting of PETCO 2 values and in the effective minimization of concurrent PETO 2 variations. We explored the persisting question of whether the levels of end-tidal CO 2 manipulations commonly used in human calibrated fMRI experiments can be expected to elicit significant changes in global CMRO 2 . We circumvented some of the key traditional challenges by using computerized PETCO 2 and PETO 2 targeting, and performed global DCMRO 2 measurements in awake humans during graded hypercapnia and hypocapnia within a range chosen to address fMRI applications (more specifically, ranging from À6 to + 9 mm Hg). Under such conditions, we found no evidence of significant changes in global CMRO 2 during PETCO 2 manipulations. Therefore, our findings support the assumption of negligible DCMRO 2 under the conditions widely used in calibrated fMRI studies of awake humans.
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